Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study-Reference-Cited by-同舟云学术

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study

Published:2017-10 Issue: Volume:61 Page:33-38
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Barritt A.S.,Gitlin Norman,Klein Samuel,Lok Anna S.,Loomba Rohit,Malahias Laura,Powell Margaret,Vos Miriam B.,Weiss L. Michael,Cusi Kenneth^ORCID,Neuschwander-Tetri Brent A.,Sanyal Arun

Funder

Gilead

Merck

NuSirt

Genfit

Promedior

Kinemed

Adheron

Tobira

Immuron

Galmed

Intercept

Arisaph

Shire

BMS

Galectin

NGM

Siemens

Eli Lilly

Octeta

Daiichi-Sankyo Inc.

Janssen

Lilly

Novartis

Novo Nordisk

Nordic

Zydus

Elsevier

UptoDate

TARGET PharmaSolutions Inc.

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference17 articles.

1. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study;Adams;Am. J. Gastroenterol.,2009

2. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994;Lazo;Am. J. Epidemiol.,2013

3. The prevalence and etiology of elevated aminotransferase levels in the United States;Clark;Am. J. Gastroenterol.,2003

4. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease;Harrison;Gut,2008

5. Nonalcoholic fatty liver disease: a systematic review;Rinella;JAMA,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease;Cell Metabolism;2024-08

2. High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort;American Journal of Gastroenterology;2024-05-09

3. A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease;Annals of Hepatology;2024-03

4. Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018;PLOS ONE;2024-02-26

5. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort;Clinical Gastroenterology and Hepatology;2023-10